
Organogenesis Holdings (ORGO) Stock Forecast & Price Target
Organogenesis Holdings (ORGO) Analyst Ratings
Bulls say
Organogenesis Holdings Inc. has demonstrated potential for improved performance despite facing mixed results due to market dynamics and upcoming structural changes in reimbursement. The company is poised for growth, with a projected increase in operating profit as it capitalizes on an expansive portfolio of regenerative medicine products within an underpenetrated market. Additionally, favorable adjustments in reimbursement rates and a strategy focused on capturing market share in a consolidating space further bolster the outlook for the company's stock.
Bears say
Organogenesis Holdings Inc. faces a challenging outlook due to anticipated stagnation in financial performance, with no improvement expected in fiscal year 2026 from increased research and development costs, although a potential reduction in selling, general, and administrative expenses is noted. The company is at risk of insufficient growth in its PuraPly product line, coupled with adverse implications from Medicare Part B pricing on amniotic products and heightened competition that could limit market share gains. Additionally, the firm may encounter hurdles due to slower adoption rates for new products, regulatory challenges, and potentially negative clinical trial outcomes, all of which contribute to a negative sentiment about its future performance.
This aggregate rating is based on analysts' research of Organogenesis Holdings and is not a guaranteed prediction by Public.com or investment advice.
Organogenesis Holdings (ORGO) Analyst Forecast & Price Prediction
Start investing in Organogenesis Holdings (ORGO)
Order type
Buy in
Order amount
Est. shares
0 shares